SG11201610624WA - Anti-cd22 antibody-drug conjugates and methods of using thereof - Google Patents

Anti-cd22 antibody-drug conjugates and methods of using thereof

Info

Publication number
SG11201610624WA
SG11201610624WA SG11201610624WA SG11201610624WA SG11201610624WA SG 11201610624W A SG11201610624W A SG 11201610624WA SG 11201610624W A SG11201610624W A SG 11201610624WA SG 11201610624W A SG11201610624W A SG 11201610624WA SG 11201610624W A SG11201610624W A SG 11201610624WA
Authority
SG
Singapore
Prior art keywords
antibody
methods
drug conjugates
conjugates
drug
Prior art date
Application number
SG11201610624WA
Other languages
English (en)
Inventor
Rong-Hwa Lin
Shih-Yao Lin
Yu-Chi Hsieh
Chiu-Chen Huang
Shu-Hua Lee
Yu-Ying Tsai
Yu-Chin Lin
Original Assignee
Bioalliance Cv
Abgenomics Internat Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioalliance Cv, Abgenomics Internat Inc filed Critical Bioalliance Cv
Publication of SG11201610624WA publication Critical patent/SG11201610624WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
SG11201610624WA 2014-06-20 2015-06-19 Anti-cd22 antibody-drug conjugates and methods of using thereof SG11201610624WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462015320P 2014-06-20 2014-06-20
PCT/US2015/036721 WO2015196089A1 (en) 2014-06-20 2015-06-19 Anti-cd22 antibody-drug conjugates and methods of using thereof

Publications (1)

Publication Number Publication Date
SG11201610624WA true SG11201610624WA (en) 2017-01-27

Family

ID=54936143

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201610624WA SG11201610624WA (en) 2014-06-20 2015-06-19 Anti-cd22 antibody-drug conjugates and methods of using thereof

Country Status (14)

Country Link
US (1) US20160015831A1 (ru)
EP (1) EP3157961A4 (ru)
JP (1) JP2017523958A (ru)
KR (1) KR20170027774A (ru)
CN (1) CN106661123A (ru)
AR (1) AR100919A1 (ru)
AU (1) AU2015276924A1 (ru)
BR (1) BR112016029842A2 (ru)
CA (1) CA2952865A1 (ru)
IL (1) IL249394A0 (ru)
RU (1) RU2017101681A (ru)
SG (1) SG11201610624WA (ru)
TW (1) TW201613641A (ru)
WO (1) WO2015196089A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201504887TA (en) 2012-12-21 2015-07-30 Bioalliance Cv Hydrophilic self-immolative linkers and conjugates thereof
CN106661124A (zh) 2014-06-20 2017-05-10 荷商台医(有限合伙)公司 抗叶酸受体α(FRA)抗体‑药物缀合物及其使用方法
MD3313845T2 (ro) * 2015-06-29 2021-02-28 Immunogen Inc Conjugați cu anticorpi având cisteină modificată prin inginerie genetică
EP3400239B1 (en) 2016-01-08 2021-06-02 AltruBio Inc. Tetravalent anti-psgl-1 antibodies and uses thereof
GB201610512D0 (en) * 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
CA3044391A1 (en) 2016-11-23 2018-05-31 Immunogen, Inc. Selective sulfonation of benzodiazepine derivatives
CN110872339A (zh) * 2018-08-30 2020-03-10 中国人民解放军军事科学院军事医学研究院 含有芳硝基的连接子、含连接子的抗体偶联药物及连接子的用途
WO2020253879A1 (zh) * 2019-06-21 2020-12-24 甘李药业股份有限公司 一种双特异性嵌合抗原受体
IT202100033002A1 (it) * 2021-12-29 2023-06-29 Diatheva S R L Anticorpi umani e loro usi

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3272695A (en) * 1994-08-12 1996-03-07 Immunomedics Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US8877901B2 (en) * 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US7591994B2 (en) * 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US8420086B2 (en) * 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
WO2007103288A2 (en) * 2006-03-02 2007-09-13 Seattle Genetics, Inc. Engineered antibody drug conjugates
UA95958C2 (en) * 2006-05-30 2011-09-26 Дженентек, Инк. Antibody that binds to cd22, immunoconjugates and uses therefor
WO2007140371A2 (en) * 2006-05-30 2007-12-06 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
US8742076B2 (en) * 2008-02-01 2014-06-03 Genentech, Inc. Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
CN114246952A (zh) * 2010-06-08 2022-03-29 基因泰克公司 半胱氨酸改造的抗体和偶联物
US8852599B2 (en) * 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
AR091701A1 (es) * 2012-07-09 2015-02-25 Genentech Inc Anticuerpos anti-cd22 e inmunoconjugados
HUE048574T2 (hu) * 2012-07-12 2020-08-28 Hangzhou Dac Biotech Co Ltd Sejthez kötõdõ molekulák citotoxikus szerekkel képzett konjugátumai
WO2014057118A1 (en) * 2012-10-12 2014-04-17 Adc Therapeutics Sarl Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
US9107960B2 (en) * 2012-12-13 2015-08-18 Immunimedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
EP4035689A1 (en) * 2012-12-13 2022-08-03 Immunomedics Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
SG11201504887TA (en) * 2012-12-21 2015-07-30 Bioalliance Cv Hydrophilic self-immolative linkers and conjugates thereof
PT2953976T (pt) * 2013-02-08 2021-06-23 Novartis Ag Sítios específicos de modificação de anticorpos para preparar imunoconjugados

Also Published As

Publication number Publication date
IL249394A0 (en) 2017-02-28
EP3157961A1 (en) 2017-04-26
CN106661123A (zh) 2017-05-10
TW201613641A (en) 2016-04-16
KR20170027774A (ko) 2017-03-10
EP3157961A4 (en) 2018-01-24
AU2015276924A1 (en) 2017-01-05
US20160015831A1 (en) 2016-01-21
CA2952865A1 (en) 2015-12-23
JP2017523958A (ja) 2017-08-24
WO2015196089A1 (en) 2015-12-23
BR112016029842A2 (pt) 2017-10-24
AR100919A1 (es) 2016-11-09
RU2017101681A (ru) 2018-07-20

Similar Documents

Publication Publication Date Title
IL261428A (en) Antibody-drug conjugates based on eribulin and methods of use
IL290959A (en) Preparations containing antibody-drug conjugates and methods for their production
IL261493A (en) Napi2b-targeted antibody conjugates - drug and methods of using them
IL248961A0 (en) Oristatin histories and their conjugations
IL249647B (en) Intended conjugates and particles and their formulations
ZA201607385B (en) Anti-ptk7 antibody-drug conjugates
PL3204018T3 (pl) Neoadiuwantowe zastosowanie koniugatów przeciwciało-lek
EP3151830A4 (en) Anti-her2 antibody-maytansine conjugates and methods of use thereof
PT3102244T (pt) Conjugados de anticorpo-fármaco e imunotoxinas
IL249394A0 (en) Anti-cd22 drug-antibody conjugates and methods of using them
EP3129402A4 (en) Site-specific antibody-drug glycoconjugates and methods
PL3102606T3 (pl) Koniugaty przeciwciało-lek i immunotoksyny
HK1258409A1 (zh) 抗cd22抗體-美登木素綴合物及其使用方法
HK1256368A1 (zh) 加利車黴素-抗體-藥物綴合物和使用方法
ZA201608327B (en) Curcumin-peptide conjugates and formulations thereof
ZA201703398B (en) Pharmaceutical composition and methods
IL246489A0 (en) Methods for using anti-steap1 antibodies and immunoconjugates